Full Year
TECH — FY2026 Annual Financial Report Analysis
Bio-Techne's FY2026 sales were flat at $1.22B (0% organic); GAAP EPS jumped to $1.16 as prior-year impairment and arbitration charges fell away, while adjusted EPS held at $1.93 ahead of its pending $73/share sale to Merck KGaA.